logo
New minimally invasive treatment for leaky heart valve at National Heart Centre Singapore

New minimally invasive treatment for leaky heart valve at National Heart Centre Singapore

Straits Timesa day ago

Madam Tay Sioh Lian, who was the first patient in Singapore to undergo the Pascal transcatheter valve repair, with NHCS CEO Yeo Khung Keong (left) and deputy CEO Jack Tan. PHOTO: LIANHE ZAOBAO
SINGAPORE – In 2022, Madam Tay Sioh Lian began experiencing bouts of breathlessness while walking or climbing the stairs.
'I couldn't even walk 30 steps,' recalled Madam Tay, who was then 74 years old.
During a check-up, a geriatrician detected a heart murmur – a whooshing sound that occurs when blood moves abnormally over the heart valves – and referred her to the National Heart Centre Singapore (NHCS). She was diagnosed with a leaky heart valve in July 2024.
Also known as mitral regurgitation, the condition occurs when the heart's mitral valve does not close tightly, causing blood to flow backward into the heart.
This can lead to fatigue and breathlessness, and can be life-threatening for those with existing heart failure.
Globally, about 3 per cent of people over the age of 70 suffer from moderate to severe leaky heart valve, with the prevalence of the condition increasing with age.
Madam Tay's condition was severe, but traditional open-heart surgery – typically used to replace or repair the valve – was considered unsuitable for her.
This was because the retired secondary school teacher was deemed high-risk due to her existing medical conditions, such as hypertension and dyslipidaemia – a condition where blood lipid levels are either too high or low, which can disrupt cardiovascular health.
NHCS offered Madam Tay a safer, less-invasive treatment, and in February 2025, she became the first patient in Singapore to undergo the Pascal transcatheter valve repair.
Developed by American medtech firm Edwards Lifesciences, the Pascal device works like a tiny clip, holding the leaky valve in place so that it can close properly and enable blood to flow normally again.
It is inserted into the body via a small incision made in the leg, and guided up to the heart via a catheter, or a thin, flexible tube.
The device comes in two sizes to suit the different anatomies of patients. It has components that reduce tension on mitral leaflets – or the flaps of a valve – and enhance flexibility and manoeuvrability during the procedure.
'The Pascal device's innovative design allows us to repair damaged heart valves with precision and control, all through a small incision,' said Assistant Professor Wong Ningyan, a consultant with NHCS' cardiology department.
While open-heart surgery remains the best option for treating leaky heart valves as it has a more established track record, the Pascal procedure provides an alternative to those who are unable to go through traditional surgery, he said.
Prof Wong, who was part of the multidisciplinary team that performed the procedure on Madam Tay, noted that patients can typically return home and resume their regular activities within days. This is much faster than the several weeks required after open-heart surgery.
The patients also experience less discomfort, he added.
Madam Tay, who is now 77, said: 'The day after the procedure, I was already back home and doing my usual activities like bathing and walking, and after a week, I could do some light household chores.'
Since February, five patients – all aged 70 and above – have undergone the Pascal procedure.
It is the latest of the minimally invasive valve procedures offered by NHCS. The centre also provides transcatheter aortic valve implantation – where a new aortic valve is delivered to the heart via a catheter – and the Mitraclip treatment, which also uses a clip to close the mitral valve but is meant for patients with different anatomies.
'By expanding our treatment options, we can now offer more personalised care appropriate for each patient's unique health needs,' said NHCS chief executive officer Yeo Khung Keong.
'For patients who previously had few alternatives, this advancement could mean the difference between continued suffering and a significantly improved quality of life,' said Prof Yeo, who was also involved in Madam Tay's procedure.
Join ST's WhatsApp Channel and get the latest news and must-reads.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New minimally invasive treatment for leaky heart valve at National Heart Centre Singapore
New minimally invasive treatment for leaky heart valve at National Heart Centre Singapore

Straits Times

timea day ago

  • Straits Times

New minimally invasive treatment for leaky heart valve at National Heart Centre Singapore

Madam Tay Sioh Lian, who was the first patient in Singapore to undergo the Pascal transcatheter valve repair, with NHCS CEO Yeo Khung Keong (left) and deputy CEO Jack Tan. PHOTO: LIANHE ZAOBAO SINGAPORE – In 2022, Madam Tay Sioh Lian began experiencing bouts of breathlessness while walking or climbing the stairs. 'I couldn't even walk 30 steps,' recalled Madam Tay, who was then 74 years old. During a check-up, a geriatrician detected a heart murmur – a whooshing sound that occurs when blood moves abnormally over the heart valves – and referred her to the National Heart Centre Singapore (NHCS). She was diagnosed with a leaky heart valve in July 2024. Also known as mitral regurgitation, the condition occurs when the heart's mitral valve does not close tightly, causing blood to flow backward into the heart. This can lead to fatigue and breathlessness, and can be life-threatening for those with existing heart failure. Globally, about 3 per cent of people over the age of 70 suffer from moderate to severe leaky heart valve, with the prevalence of the condition increasing with age. Madam Tay's condition was severe, but traditional open-heart surgery – typically used to replace or repair the valve – was considered unsuitable for her. This was because the retired secondary school teacher was deemed high-risk due to her existing medical conditions, such as hypertension and dyslipidaemia – a condition where blood lipid levels are either too high or low, which can disrupt cardiovascular health. NHCS offered Madam Tay a safer, less-invasive treatment, and in February 2025, she became the first patient in Singapore to undergo the Pascal transcatheter valve repair. Developed by American medtech firm Edwards Lifesciences, the Pascal device works like a tiny clip, holding the leaky valve in place so that it can close properly and enable blood to flow normally again. It is inserted into the body via a small incision made in the leg, and guided up to the heart via a catheter, or a thin, flexible tube. The device comes in two sizes to suit the different anatomies of patients. It has components that reduce tension on mitral leaflets – or the flaps of a valve – and enhance flexibility and manoeuvrability during the procedure. 'The Pascal device's innovative design allows us to repair damaged heart valves with precision and control, all through a small incision,' said Assistant Professor Wong Ningyan, a consultant with NHCS' cardiology department. While open-heart surgery remains the best option for treating leaky heart valves as it has a more established track record, the Pascal procedure provides an alternative to those who are unable to go through traditional surgery, he said. Prof Wong, who was part of the multidisciplinary team that performed the procedure on Madam Tay, noted that patients can typically return home and resume their regular activities within days. This is much faster than the several weeks required after open-heart surgery. The patients also experience less discomfort, he added. Madam Tay, who is now 77, said: 'The day after the procedure, I was already back home and doing my usual activities like bathing and walking, and after a week, I could do some light household chores.' Since February, five patients – all aged 70 and above – have undergone the Pascal procedure. It is the latest of the minimally invasive valve procedures offered by NHCS. The centre also provides transcatheter aortic valve implantation – where a new aortic valve is delivered to the heart via a catheter – and the Mitraclip treatment, which also uses a clip to close the mitral valve but is meant for patients with different anatomies. 'By expanding our treatment options, we can now offer more personalised care appropriate for each patient's unique health needs,' said NHCS chief executive officer Yeo Khung Keong. 'For patients who previously had few alternatives, this advancement could mean the difference between continued suffering and a significantly improved quality of life,' said Prof Yeo, who was also involved in Madam Tay's procedure. Join ST's WhatsApp Channel and get the latest news and must-reads.

Eye care giant Alcon keeps 'lens' on the future with expanded manufacturing and logistics facility in Tuas, Singapore News
Eye care giant Alcon keeps 'lens' on the future with expanded manufacturing and logistics facility in Tuas, Singapore News

AsiaOne

time2 days ago

  • AsiaOne

Eye care giant Alcon keeps 'lens' on the future with expanded manufacturing and logistics facility in Tuas, Singapore News

Eye care-device giant Alcon officially opened its expanded state-of-the art manufacturing and logistics facility in Tuas Biomedical Park on Friday (June 27) morning. This brings Alcon's investments in Singapore to more than US$600 million (S$765 million) since it began operations in Singapore back in 2005. The completed Tuas facility is one of the Swiss-American firm's largest high-tech manufacturing sites with Industry 4.0 capabilities, advanced automation and smart manufacturing systems to meet the increasing global demand for its contact lenses. Amid a growing middle class and rising demand for quality healthcare, the Asia-Pacific region continues to be the fastest-growing market for medical technology, with its market value projected to reach nearly S$300 billion by 2030. This puts the region second only to the US as a source of demand for medical technology (Medtech). "Singapore is home to some of the world's best-in-class Medtech manufacturing palnts. The sector has been growing steadily, with a manufacturing output of S$19.4 billion in 2023. This marks a $5.2 billion increase over the past decade," said Senior Minister of State for Trade and Industry Low Yen Ling at the opening ceremony of Alcon's expanded facility. Beyond strengthening innovation and supply chain resilience within Singapore's MedTech ecosystem, Alcon's investment is also expected to benefit Singaporean workers and small- and medium-sized enterprises (SMEs) in Singapore. Muhammad Haiqal Bin Sapuan, an associate supervisor at Alcon made the switch from the oil and gas industry, through the Career Conversion Programme (CCP), in 2022 to have more time with his family. A year and a half into his role as a senior technician, he was nominated by his peers to step up as an associate supervisor. [[nid:707984]] "That recognition gave me confidence. I started off as an interim, and it was tough at first, but the team's support made the difference," said Haiqal. To date, nearly 180 Singaporean workers have benefitted from the CCP to become Alcon associates. Alcon's new facility is expected to create new job opportunities in production operations, quality control and supply chain management. It is also expected to strengthen innovation and supply chain resilience within Singapore's Medtech ecosystem through initiatives such as the Partnership for Capability Transformation, which partners local SMEs to buiild capabilities from precision moulding to packaging, helping them to scale and compete globally. [[nid:715407]] editor@

Swiss-American eye care firm Alcon launches expanded Tuas manufacturing facility
Swiss-American eye care firm Alcon launches expanded Tuas manufacturing facility

Business Times

time3 days ago

  • Business Times

Swiss-American eye care firm Alcon launches expanded Tuas manufacturing facility

[SINGAPORE] Alcon, a Swiss-American pharmaceutical and medical device company specialising in eye care products, opened its expanded manufacturing and logistics facility in Tuas on Friday (Jun 27). This brings its total investment in Singapore to more than US$600 million since opening its first manufacturing site here in 2005. Located in Tuas Biomedical Park, the facility is one of Alcon's largest manufacturing sites, featuring advanced automation, smart manufacturing systems and industry 4.0 capabilities to support the increasing global demand for its contact lenses. It is also designed for operational efficiency and sustainability, with automation; digital systems; and features that reduce energy use, water consumption and waste. It has achieved zero waste to landfill and supports scalable production for global demand. Speaking at the launch event, Senior Minister of State for Trade and Industry Low Yen Ling said the partnership between Alcon and Singapore over the past 20 years exemplifies how deep, sustained collaboration can drive industrial growth and create meaningful careers for Singaporeans. 'Singapore is home to some of the world's best-in-class medtech manufacturing plants. The sector has been growing steadily, with a manufacturing output of S$19.4 billion in 2023, a nearly fourfold increase over the past decade,' she said. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up In a statement, Alcon said that the expansion is expected to create new 'high-value' jobs in areas such as manufacturing, quality control and distribution management. It will also support Singapore's ambition to grow its medtech workforce, which comprises over 400 companies and employs more than 16,000 people as of 2024. The company partners with local institutions and workforce programmes to build skills in precision engineering, biomedical sciences and artificial intelligence automation, supporting the growth of Singapore's medtech sector. One initiative is the Career Conversion Programme (CCP), which allowed the firm to tap into a broader, more diverse talent pool, including mid-career switchers and individuals seeking new roles. To date, nearly 180 associates have benefited. Muhammad Haiqal Sapuan, a beneficiary of the programme, worked in the oil and gas sector previously and joined Alcon as a senior technician in 2022. After participating in the CCP and undergoing strong mentoring, he now serves as an associate supervisor, leading a team of 15 in production technical operations. Alcon currently employs more than 25,000 people worldwide and serves over 260 million patients across 140 countries annually.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store